Literature DB >> 35586533

Pembrolizumab-Induced Steroid-Responsive Myoclonus.

Amy Gallagher1, Michael Murphy1, Ray McDermott2, Michael Alexander3, Sean O'Dowd1,4.   

Abstract

Entities:  

Keywords:  Pembrolizumab; adverse; immune checkpoint inhibitor; myoclonus; neurological

Year:  2022        PMID： 35586533      PMCID： PMC9092743          DOI： 10.1002/mdc3.13453

Source DB:  PubMed          Journal:  Mov Disord Clin Pract        ISSN： 2330-1619


× No keyword cloud information.
  8 in total

Review 1.  Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature.

Authors:  L Spain; G Walls; M Julve; K O'Meara; T Schmid; E Kalaitzaki; S Turajlic; M Gore; J Rees; J Larkin
Journal:  Ann Oncol       Date:  2017-02-01       Impact factor: 32.976

2.  Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies.

Authors:  Justin C Kao; Bing Liao; Svetomir N Markovic; Christopher J Klein; Elie Naddaf; Nathan P Staff; Teerin Liewluck; Julie E Hammack; Paola Sandroni; Heidi Finnes; Michelle L Mauermann
Journal:  JAMA Neurol       Date:  2017-10-01       Impact factor: 18.302

3.  Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial.

Authors:  Jinhyun Cho; Hae Su Kim; Bo Mi Ku; Yoon-La Choi; Razvan Cristescu; Joungho Han; Jong-Mu Sun; Se-Hoon Lee; Jin Seok Ahn; Keunchil Park; Myung-Ju Ahn
Journal:  J Clin Oncol       Date:  2018-06-15       Impact factor: 44.544

Review 4.  Neurological immune-related adverse events associated with immune checkpoint inhibitors: A review of the literature.

Authors:  Siyuan Fan; Haitao Ren; Luo Zhao; Jian Yin; Guodong Feng; Jiawei Wang; Hongzhi Guan
Journal:  Asia Pac J Clin Oncol       Date:  2020-09-07       Impact factor: 2.601

5.  Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.

Authors:  Yucai Wang; Shouhao Zhou; Fang Yang; Xinyue Qi; Xin Wang; Xiaoxiang Guan; Chan Shen; Narjust Duma; Jesus Vera Aguilera; Ashish Chintakuntlawar; Katharine A Price; Julian R Molina; Lance C Pagliaro; Thorvardur R Halfdanarson; Axel Grothey; Svetomir N Markovic; Grzegorz S Nowakowski; Stephen M Ansell; Michael L Wang
Journal:  JAMA Oncol       Date:  2019-07-01       Impact factor: 31.777

6.  Nivolumab-Induced Severe Akathisia in an Advanced Lung Cancer Patient.

Authors:  Jiro Abe; Taku Sato; Ryota Tanaka; Toshimasa Okazaki; Satomi Takahashi
Journal:  Am J Case Rep       Date:  2016-11-23

7.  Phosphodiesterase 10A IgG: A novel biomarker of paraneoplastic neurologic autoimmunity.

Authors:  Anastasia Zekeridou; Thomas Kryzer; Yong Guo; Anhar Hassan; Vanda Lennon; Claudia F Lucchinetti; Sean Pittock; Andrew McKeon
Journal:  Neurology       Date:  2019-07-17       Impact factor: 9.910

Review 8.  Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy-Review of the Literature and Future Outlook.

Authors:  Nora Möhn; Gernot Beutel; Ralf Gutzmer; Philipp Ivanyi; Imke Satzger; Thomas Skripuletz
Journal:  J Clin Med       Date:  2019-10-24       Impact factor: 4.241
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.